---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-010273"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2023-01-18T23:59:59+00:00"
generated_at: "2026-06-20T14:05:51.935150+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Fulcrum Therapeutics prices upsized public offering of 9.6M shares at $13.00, expected gross proceeds of $125M

## Summary
- Offered 9,615,384 shares at $13.00 per share; gross proceeds of $125 million.
- Underwriters granted 30-day option to purchase up to an additional 1,442,307 shares.
- Net proceeds estimated at $117.3M ($134.9M if option fully exercised).
- Goldman Sachs, SVB Securities, Piper Sandler acting as joint book-running managers.
- Offering expected to close on January 20, 2023.

## SEC filing metadata
- accession: 0001193125-23-010273
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2023-01-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000119312523010273/0001193125-23-010273-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000119312523010273/d451832d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-010273
- JSON: https://secwatch.observer/filing/0001193125-23-010273.json
- Plain text: https://secwatch.observer/filing/0001193125-23-010273.txt

## Key facts
- Material Agreements
  Fulcrum Therapeutics, Inc. entered into underwriting agreement with Goldman Sachs & Co. LLC, SVB Securities LLC and Piper Sandler & Co., as representatives of the several underwriters valued at approximately $117.3 million (effective 2023-01-17).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Goldman Sachs & Co. LLC, SVB Securities LLC and Piper Sandler & Co., as representatives of the several underwriters
  - Value: approximately $117.3 million
  - Effective: 2023-01-17
  source text: On January 17, 2023, Fulcrum Therapeutics, Inc., or Fulcrum, entered into an underwriting agreement with Goldman Sachs & Co. LLC, SVB Securities LLC and Piper Sandler & Co., as the representatives of the several underwriters, or the Underwriters, relating to an underwritten public offering of 9,615,384 shares of its common stock, par value $0.001 per share, at a price to the public of $13.00 per share, less underwriting discounts and commissions.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680581/000119312523010273/0001193125-23-010273-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.